title: Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
abstract: Most men treated with radical prostatectomy or radiation therapy for localized prostate cancer will be cured of prostate cancer; however, some men will experience treatment failure. Androgen deprivation therapy is well established in the treatment of metastatic prostate cancer. Adjuvant androgen deprivation therapy, following prostatectomy and/or radiotherapy, has been studied in the high-risk prostate cancer setting to try to reduce the risk of recurrence and improve patient outcomes. In this review, we discuss the current data for neoadjuvant and adjuvant therapy with androgen suppression, chemotherapy, and approaches with the newer hormonal agents.
authors.affiliation: Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Mailstop 8117, 12801 East 17th Avenue, Aurora, CO 80045, USA. Electronic address: elaine.lam@ucdenver.edu.
authors.forename: Elaine T
authors.initials: ET
authors.lastname: Lam
authors.forename: L Michael
authors.initials: LM
authors.lastname: Glodé
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery
chemical_list: D018931:Antineoplastic Agents, Hormonal
keywords: Adjuvant therapy; Chemotherapy; Neoadjuvant therapy; Prostate cancer